文献速递甲状腺疾病

DIO2 Thr92Ala降低甲状腺缺陷患者的2型脱碘酶活性及血清T3水平

DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究纳入140例甲状腺切除术后接受左甲状腺素(LT4)治疗的患者,其中102/140(72.8%)进行DIO2基因分型,比较手术前后激素水平并检测Thr92Ala的酶学特性。携带Thr92Ala突变等位基因的患者术后平均FT3水平显著低于野生型患者,且Thr92Ala降低D2介导的T4向T3转化,提示此类患者LT4治疗不足以充分补偿T3水平,支持个体化治疗。

要点

  • 甲状腺切除术后LT4治疗患者中,携带DIO2 Thr92Ala突变等位基因者术后平均FT3水平显著低于野生型患者。
  • 野生型患者术后FT3水平与术前相似,而突变携带者术后FT3显著降低。
  • Thr92Ala降低2型脱碘酶(D2)介导的甲状腺素向T3转化,影响细胞内和血清T3浓度。

核心结论

  • 携带Thr92Ala的甲状腺切除患者存在细胞内和血清T3浓度降低的风险增加,且LT4不能充分补偿,为无甲状腺患者个体化治疗甲状腺功能减退提供证据。

研究设计与样本

  • 比较甲状腺切除术后LT4治疗且TSH水平相似患者的术前与术后激素状态,并对102/140(72.8%)患者进行DIO2基因分型。
  • 在活细胞和相应生成的小鼠模型中检测Thr92Ala的酶学特性。
  • 共纳入140例甲状腺切除受试者,直接测量血清FT3、游离甲状腺素和TSH水平,并进行D2蛋白的免疫组化和免疫印迹。

主要发现

  • DIO2基因分型显示低FT3值与Thr92Ala相关。
  • 术后平均FT3水平在携带突变等位基因的患者中显著低于野生型患者,野生型患者术后FT3水平与术前相似。
  • -258 G/A变异与激素改变无关。
  • 内源性野生型D2与Thr92Ala亚细胞定位相同但蛋白稳定性不同。
  • Thr92Ala降低D2介导的甲状腺素向T3转化。

临床怎么用

  • 作者认为,携带Thr92Ala的甲状腺切除患者存在T3浓度降低风险且LT4不能充分补偿,为无甲状腺患者个体化治疗甲状腺功能减退提供证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: A substantial proportion of athyreotic levothyroxine (LT4)-treated patients experience hypothyroid-like symptoms. During LT4 replacement, levels of the active hormone triiodothyronine (T3) strictly depend on type 2-deiodinase (D2)-mediated activation of LT4. The Thr92Ala polymorphism and the 258 G/A in the DIO2 gene have been associated with various clinical conditions. OBJECTIVES: To investigate the effects of DIO2 polymorphisms in thyroid hormone homeostasis. DESIGN: We compared the presurgical hormonal status of thyroidectomized LT4-treated patients who had a similar thyroid-stimulating hormone (TSH) level with their postsurgery status and analyzed their DIO2 genotype in a subgroup of 102/140 (72.8%) of patients. We measured the enzymatic properties of Thr92Ala in living cells and in relevant generated mouse models. SUBJECTS AND METHODS: A total of 140 thyroidectomized subjects were included. Serum free T3 (FT3), free thyroxine, and TSH levels were directly measured. Immunohistochemistry and immunoblotting were performed for D2 protein. RESULTS: The DIO2 genotyping revealed an association between low FT3 values and Thr92Ala. Specifically, the mean postsurgery FT3 levels were significantly lower in patients carrying the mutated allele(s) than in wild-type patients, in whom FT3 postsurgical levels were similar to presurgery levels. The -258 G/A variation was not associated with hormonal alteration. We found that endogenous wild-type D2 and Thr92Ala share the same subcellular localization but differ in protein stability. Importantly, Thr92Ala reduced D2-mediated thyroxine to T3 conversion. CONCLUSIONS: Thyroidectomized patients carrying Thr92Ala are at increased risk of reduced intracellular and serum T3 concentrations that are not adequately compensated for by LT4, thus providing evidence in favor of customized treatment of hypothyroidism in athyreotic patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients. J Clin Endocrinol Metab. 2017. PMID: 28324063. doi:10.1210/jc.2016-2587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。